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Background: Economic evaluation of newborn screening poses specific methodological challenges. Amongst
others, these challenges refer to the use of quality adjusted life years (QALYs) in newborns, and which costs and
outcomes need to be considered in a full evaluation of newborn screening programmes. Because of the increasing
scale and scope of such programmes, a better understanding of the methods of high-quality economic evaluations
may be crucial for both producers/authors and consumers/reviewers of newborn screening-related economic
evaluations. The aim of this study was therefore to develop specific guidelines designed to assess and improve the
methodological quality of economic evaluations in newborn screening.
Methods: To develop the guidelines, existing guidelines for assessing the quality of economic evaluations were
identified through a literature search, and were reviewed and consolidated using a deductive iterative approach. In
a subsequent test phase, these guidelines were applied to various economic evaluations which acted as case
studies.
Results: The guidelines for assessing and improving the methodological quality of economic evaluations in
newborn screening are organized into 11 categories: “bibliographic details”, “study question and design”,
“modelling”, “health outcomes”, “costs”, “discounting”, “presentation of results”, “sensitivity analyses”, “discussion”,
“conclusions”, and “commentary”.
Conclusions: The application of the guidelines highlights important issues regarding newborn screening-related
economic evaluations, and underscores the need for such issues to be afforded greater consideration in future
economic evaluations. The variety in methodological quality detected by this study reveals the need for specific
guidelines on the appropriate methods for conducting sound economic evaluations in newborn screening.Background
Where resources needed for the production of health
benefits are scarce, decision makers need to consider
both the effectiveness and the cost-effectiveness of health
interventions. Economic evaluation is the comparative
analysis of alternative interventions with regard to both
their costs and outcomes [1]. Although economic evalua-
tions are used to inform decision making in health care,
several studies have shown that economic evaluations* Correspondence: astrid-langer@gmx.de
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reproduction in any medium, provided the ordiffer markedly in quality [2-4]. Common methodo-
logical flaws in economic evaluations relate to study de-
sign, data collection and analysis, and interpretation or
reporting of results [5]. In order to assess the methodo-
logical rigour of economic evaluations, various instru-
ments have been developed. To date, two of these
instruments have received more scrutiny than others [6],
namely the “Guidelines for authors and peer reviewers of
economic submissions to the BMJ“ [7] and the “Consen-
sus on Health Economic Criteria (CHEC) list for assess-
ment of methodological quality of economic evaluations“
[8]. Whereas the latter is a specific list of criteria for con-
ducting systematic reviews of trial-based economic eva-
luations, the former is a general checklist for assessing
economic evaluations. However, both the study questionsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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disease-specific guidelines in order to assess and improve
the methodological quality of economic evaluations in a
specific disease area [9]. For instance, in order to support
effective decision making, the Canadian Agency for
Drugs and Technologies in Health (CADTH) published
oncology guidelines which provide specific guidance for
conducting high-quality economic evaluations of oncol-
ogy products [10].
The uniqueness of child health and associated meth-
odological challenges in conducting economic evalua-
tions have already been pointed out [11]. Specific
methodological challenges also emerge in economic eva-
luations of newborn screening. For instance, there is a
lack of adequate and robust long-term data from which
useful evidence can be produced [12,13]. Besides the
dearth of long-term follow-up studies of newborn
screening programmes and the associated extrapolation
of short-term data to capture a lifetime time horizon,
other challenges pertain to the problem of appropriate
discounting, the use of quality adjusted life years
(QALYs) in newborns, and which costs and outcomes
need to be considered in a full evaluation of newborn
screening programmes. Because of the increasing scale
and scope of such programmes, a better understanding
of the methods of high-quality economic evaluations
may be crucial for both producers/authors and consu-
mers/reviewers of newborn screening-related economic
evaluations in order to assure high quality allocation
decisions in newborn screening. The aim of this study
was therefore to establish specific guidelines for assessing
and improving the methodological quality of economic
evaluations in newborn screening. These guidelines are
designed for both producers/authors and consumers/
reviewers of economic evaluations of newborn screening,
and are suitable for trial-based and model-based eco-
nomic evaluations. Additionally, the guidelines were
tested with respect to various economic evaluations in
the areas of newborn hearing screening and newborn
screening for medium-chain acyl–CoA dehydrogenase
deficiency (MCADD) using tandem mass spectrometry
(MS/MS).
Methods
In order to identify and review existing guidelines for
assessing the quality of economic evaluations, several
databases and the internet were searched. Using a de-
ductive iterative process, data from textbooks on health
economic evaluation [1,14,15], principles of good prac-
tice published by different ISPOR Task Forces [16,17],
and from several guidelines, checklists and criteria lists
[7,8,18-22] were extracted qualitatively based on general
categories identified in previous work [19]. After data ex-
traction, the relevance of each category and item withinit was discussed in relation to the development
of specific guidelines to assess and improve the meth-
odological quality of economic evaluations in newborn
screening. The final set of guidelines was developed
based on majority consensus.
In order to test the specific guidelines, they were ap-
plied to economic evaluations which were identified
through a systematic review of the literature: economic
evaluations of newborn hearing screening and economic
evaluations of newborn screening for inherited metabolic
disorders including MCADD by MS/MS. The following
databases were searched from inception to April 2012
for relevant studies: HTA database, NHS Economic
Evaluation Database, Pediatric Economic Database,
PubMed, Web of Science. The literature search for eco-
nomic evaluations of newborn hearing screening used
the following terms: (“newborn” or “neonatal” or “in-
fant”) combined with (“economic” or “cost”) and (“hear-
ing” or “deaf”) and “screening”. The literature search for
economic evaluations of newborn screening for inherited
metabolic disorders including MCADD by MS/MS used
the following terms: (“newborn” or “neonatal” or “in-
fant”) combined with (“economic” or “cost”) and
(“screening” or “tandem mass spectrometry” or “MS/MS
screening”) and (“metabolic disorders” or “MCADD” or
“MCAD” or “medium-chain acyl-CoA dehydrogenase de-
ficiency”). The searches were limited by study design
(cost analysis, cost-minimization analysis, cost-
effectiveness analysis, cost-utility analysis, and cost-
benefit analysis), year (2000 – 2012) and language of
publication (English, French or German). In addition, the
economic analyses should be fully described and trans-
parent. Further studies were identified by examining the
reference lists of several systematic reviews and health
technology assessments in the areas of newborn hearing
screening [23-25] and newborn screening for inherited
metabolic disorders including MCADD by MS/MS
[12,13,26,27]. The full list of sources and the search
strategy are available from the authors.
Results
The guidelines for assessing and improving the meth-
odological quality of economic evaluations in newborn
screening are organized into 11 categories: “bibliographic
details”, “study question and design”, “modelling”, “health
outcomes”, “costs”, “discounting”, “presentation of
results”, “sensitivity analyses”, “discussion”, “conclusions”,
and “commentary”. The full set of guidelines is presented
in Table 1.
A. Bibliographic details
In addition to the common bibliographic details (author
(s), title, and source of publication), details on the publi-
cation type (e.g., peer-reviewed journal article, non-peer-
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2. Institutional affiliation of author(s)
3. Source of funding
4. Title
5. Source of publication
6. Publication type









9. Type of economic evaluation
10. Study population





4. Sources used to develop
and/or populate the model
5. Cycle length
6. Health states and transition
7. Model validation
D. Health outcomes
1. Health outcomes measured
in natural units
a. Type of health outcome measure
used in the economic evaluation
b. Method of measurement
c. Source of data
2. Health outcomes adjusted by utility
weights or health state preference scores
a. Type of health outcome measure used
in the economic evaluation
b. Method of valuation
c. Source of data
3. Health outcomes measured
in monetary units
a. Type of health outcome
measure used in the economic
evaluation
b. Method of valuation
Table 1 Specific guidelines for assessing and improving
the methodological quality of economic evaluations of
newborn screening (Continued)
c. Source of data
4. Intermediate health outcomes
a. Type of health outcome measure
used in the economic evaluation
b. Method of measurement
c. Source of data
5. Non-health outcomes
a. Type of health outcome measure
used in the economic evaluation
b. Method of measurement
c. Source of data
E. Costs
1. Patient-related costs
a. Cost categories considered in
the economic evaluation
b. Measurement of resource data
c. Valuation of resource data
d. Source of data
2. Programme-related costs
a. Cost categories considered in
the economic evaluation
b. Measurement of resource data
c. Valuation of resource data
d. Source of data
F. Discounting
1. Discount rate for costs
2. Discount rate for health outcomes
3. Justification of discount rates
G. Presentation of results
1. Absolute and incremental health
outcomes per newborn
2. Absolute and incremental costs
per newborn
3. ICER for the primary outcome
measure
4. Present values and trends of costs
and health outcomes at the
population level
5. Present values and trends of costs
at the population level differentiated
by payer




3. Methods of sensitivity analyses
4. Results of sensitivity analyses
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Table 1 Specific guidelines for assessing and improving
the methodological quality of economic evaluations of
newborn screening (Continued)
I. Discussion
1. Limitations of the study
2. Generalizability and transferability
of the economic evaluation results
3. Ethical and distributional issues
J. Conclusions
1. Validity of conclusions with regard
to the results of the economic evaluation
2. Validity of conclusions with regard
to the objective of the economic evaluation
K. Commentary
1. Selection of comparators
2. Validity of estimate of measure
of effectiveness
3. Validity of estimate of measure
of health outcome
4. Validity of estimate of costs
5. Other issues
6. Implications of the economic evaluation
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or book section) should be provided in order to obtain
information on the methods of quality control during
the publication process. Furthermore, the institutional
affiliation of author(s) and the source of funding should
be stated because both items can act as an indicator for
potential conflicts of interest.
B. Study question and design
First, a clearly defined and answerable study question
should be posed. This should encompass a detailed de-
scription of the screening intervention under evaluation
and its comparator. Furthermore, the target population
of the screening intervention and the time horizon over
which costs and health outcomes are likely to accumu-
late should be stated. The perspective and the time hori-
zon of the analysis should be clearly stated, and the
reasons underlying these choices should be made trans-
parent. Fixing these boundaries of the study determines
which elements of costs and benefits should be included
in the economic evaluation. If the primary purpose of
the economic evaluation is to assist health policy makers
in making optimal societal decisions, a societal perspec-
tive should be chosen, i.e. all relevant short- (costs of
screening and diagnostic follow-up) and long-term costs
(costs for therapy, rehabilitation, education and social
services, and lost productivity), and consequences such
as morbidity or mortality, should be included. In the caseof newborn screening programmes, this societal perspec-
tive usually implies that a lifetime time horizon should
be adopted. To judge the generalizability and transfer-
ability of the results of economic evaluation, the setting,
including time and place of intervention, should be
described in detail, because the type of setting (e.g., in-
patient or outpatient) can have a great influence on
screening coverage. Finally, the study design (clinical
study or decision-analytic model), the type of economic
evaluation (cost-consequences analysis, cost-minimization
analysis, cost-effectiveness analysis, cost-utility analysis,
and cost-benefit analysis), and the primary outcome mea-
sure used in the economic evaluation should be stated,
and the study population should be described in detail to
assess the generalizability of economic evaluation results
with regard to the target population of the screening
intervention.
C. Modelling
Economic evaluations based on decision-analytic models
synthesize the available evidence systematically and pro-
vide projected estimates of long-term outcomes when
long-term data are missing. Thus, decision-analytic mod-
els can support policy decisions for newborn screening
programmes [28]. First, the model type (cohort model or
patient-level simulation model) should be specified. Fur-
thermore, the model structure should be described in de-
tail, including statement of decision problem and scope,
and it should be appropriate for addressing the study
question. In addition, all model assumptions and asso-
ciated choices should be stated and justified, and all
sources used to develop and/or populate the model
should be stated and justified. Furthermore, in Markov
models, information on cycle length, and health states
and transitions should be provided. Finally, with regard
to model validation, internal and external validations
should be described. A more detailed framework for
assessing the quality of decision-analytic models is avail-
able [21], which is based on a comprehensive review of
the respective literature [29]. It is recommended that
producers/authors and consumers/reviewers of newborn
screening-related economic evaluations consult these or
comparable good modelling practice guidelines for a
more detailed assessment of the transparency and quality
of model-based economic evaluations.
D. Health outcomes
Initially, it is necessary to determine which type of health
outcome measure was used in the economic evaluation
to assess whether all relevant consequences of the condi-
tion under evaluation were considered. The choice of
health outcome measure should be based on the condi-
tion(s), intervention, and health policy setting and audi-
ence. Common types of health outcome measure used in
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health outcomes measured in natural units (e.g., life-
years gained or cases correctly diagnosed), and
preference-based health outcomes such as the quality
adjusted life year (QALY). In general, health outcome
measures should be used that are relevant to the patient.
Especially with regard to economic evaluations of new-
born screening for inherited metabolic disorders, appro-
priate preference-based health outcomes which integrate
mortality and morbidity in a single outcome measure
should be used to value meaningful differences between
MS/MS and alternatives in terms of health-related qual-
ity of life. Furthermore, in contrast to measuring out-
come by the number of cases correctly diagnosed,
preference-based health outcomes such as QALYs can be
used to compare screening interventions that are tar-
geted at different disorders. However, the use of QALYs
in child health care poses serious methodological chal-
lenges which must be considered carefully in the search
for an appropriate outcome measure [30,31]. Other
health outcomes in newborn screening-related economic
evaluations are intermediate health outcomes, non-
health outcomes, or health outcomes measured in mon-
etary units. In all cases, the type of health outcome or ef-
fectiveness measure influences its measurement and
valuation. The methods used to measure and value
health outcomes should be the most appropriate ones
for the condition under evaluation and the study ques-
tion, and should be stated for reasons of transparency
and comparability of economic evaluations. Finally, the
source of data used to calculate the health outcomes
should be provided as well, including the evidence of ef-
fectiveness. One of the main weaknesses in economic
evaluations of newborn screening is usually in the area
of epidemiology [12]. There is a lack of data to directly
compare health outcomes for both screened and un-
screened cohorts. Furthermore, readers should be aware
that some sources of data such as systematic reviews
might be more valid than others such as expert opinions.
To validate data and modelling assumptions, epidemiolo-
gists and clinicians should be consulted.
E. Costs
Contrary to many other health technologies, interven-
tions in newborn screening generate costs at the admin-
istrative level and at the level of the individual patient.
Patient-related costs consist of direct medical costs
(screening costs, treatment costs, and downstream health
costs, such as monitoring and managing of cases
detected), direct non-medical costs (e.g., travel expenses
and time costs of parents accompanying their child, or
costs associated with institutional care and special edu-
cation), and indirect costs (costs for lost productivity).
With regard to indirect costs in economic evaluations ofnewborn screening, it is essential to value both the pa-
tient and the caregiver time. A critical review of existing
valuation methods can be found elsewhere [32].
Programme-related costs are all “costs incurred at the
administrative levels outside the point of delivery of
health care to beneficiaries“ [33], such as costs for the
implementation, organization, administration, monitor-
ing, and evaluation of the screening programme and
costs for tracking. In general, all resources that are rele-
vant to the study perspective should be identified, mea-
sured, and valued. For instance, additional health care
costs prior to diagnosis may be included for conditions
not screened for [13], or unrelated costs that accrue
from the intervention during life-years gained may be
considered as well, an issue which is controversial in the
literature [34-39]. Both the costing and the valuation
method (e.g., adjustment for inflation) used should be
stated and justified, and the sources used to obtain data
on resource utilisation and unit costs should be reported.
In order to enhance generalizability and transferability,
quantities and unit costs should be reported separately.F. Discounting
In newborn screening-related economic evaluations with
a longer time horizon than one year, costs and health
outcomes should be discounted. However, discount rates
can have a great influence on the results of an economic
evaluation [40,41]. For instance, studies which discount
costs more than they discount health outcomes will re-
sult in a relatively low ICER [13]. Therefore, the choice
of discount rates should be stated and justified: both a
discount rate for costs and a discount rate for health out-
comes should be provided. Furthermore, a justification
of the discount rates should be given – i.e., the rationale
for the choice of discount model and discount rates in
the base case and in the sensitivity analyses, and for the
use of different or common discount rates for costs and
health outcomes should be provided.G. Presentation of results
First, both the costs and the health outcomes should be
presented per newborn, and in both disaggregated and
aggregated forms. Furthermore, an incremental cost-
effectiveness ratio (ICER) should be provided for the pri-
mary outcome measure used in the economic analysis.
Present values and trends of costs and health outcomes
at the population level should be reported as well. Add-
itionally, in terms of costs, present values and trends
should be differentiated by payer because in newborn
screening costs are borne by different payers (e.g., health
insurance, patient, or state and federal government). Fi-
nally, the coverage of screening should be reported
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effectiveness of alternative screening strategies.
H. Sensitivity analyses
In the area of newborn screening for inherited metabolic
disorders, various factors, such as prevalence of the dis-
order, or frequency of adverse outcomes, influence the
ICER [42], and therefore should be varied in sensitivity
analyses in order to assess the impact on economic
evaluation results and conclusions. Parameter uncer-
tainty should be addressed, including a statement and
justification of the ranges or distributions of parameters
used for sensitivity analyses. In model-based economic
evaluations, modelling uncertainty should be investigated
as well because structure, methods, and assumptions of
models are subject to uncertainty. Furthermore, methods
(univariate or multivariate sensitivity analyses, probabilis-
tic sensitivity analyses, threshold analyses and analyses of
extremes or best/worst case analyses) and results of sen-
sitivity analyses should be reported.
I. Discussion
First, the limitations of the study should be discussed.
For instance, in newborn screening-related economic
evaluations, one of the main constraints and weaknesses
refers to the lack of long-term data [12]. Second, both
generalizability and transferability of the study results
should be discussed, which relate to the extent to which
the economic evaluation results are applicable to differ-
ent settings. Methodological (e.g., perspective, discount
rate), health care system (e.g., absolute and relative prices
in health care), and population characteristics (e.
g., disease prevalence) are factors that influence the trans-
ferability of economic evaluation results [43] in
general as well as in newborn screening. Finally, ethical
and distributional issues should also be considered, be-
cause both are essential for economic evaluations with re-
spect to rare and disabling conditions. In the case of
economic evaluations of newborn screening, ethical
issues which might be of concern to users include the
principles of beneficence (“finding the evidence of bene-
fit”), non-maleficence (“finding the harm”), autonomy
(“the right to choose, and the protection of those with
diminished autonomy”), and justice (“distributive justice”)
[44]. For instance, ethical challenges emerging from the
use of QALYs for disabling conditions should be
addressed [45]. Other ethical issues are associated with
the use of MS/MS: detection of diseases for which there
is no (effective) treatment, detection of diseases whose
natural history is not (well) understood, detection of ma-
ternal variance, detection of carriers, and finding the evi-
dence of benefit [44]. However, benefits from the early
and correct diagnosis of a newborn with a largely untreat-
able disorder relate to the prevention of misdiagnosis,reassurance of parents, and enabling future reproductive
choices [44]. In economic evaluations of newborn screen-
ing for inherited metabolic disorders, ethical issues
regarding antenatal screening may also be included [13].
Furthermore, the distribution of costs and benefits should
be considered [46].
J. Conclusion
The conclusions should follow from the results of the eco-
nomic evaluation and should answer the study question.
K. Commentary
The commentary of the consumer/reviewer of the eco-
nomic evaluation should be a critical summary of the
overall reliability and generalizability of the economic
evaluation and include the following issues: Selection of
comparators, validity of estimate of measure of effective-
ness, validity of estimate of measure of health outcome,
validity of estimate of costs, other issues, and implica-
tions of the economic evaluation. These issues were
adapted from the NHS EED structured abstract format
[47].
Application of the guidelines for assessing and improving
economic evaluations in newborn screening
In the following, the experiences of applying the guide-
lines to economic evaluations in the areas of newborn
screening for inherited metabolic disorders including
MCADD by MS/MS and newborn hearing screening are
reported.
Economic evaluations of newborn hearing screening
In the area of newborn hearing screening, the guidelines
were applied to 21 economic evaluations [23-25,48-65],
of which an overview is provided in Additional file 1.
These studies were heterogeneous with regard to target
population (all newborns or newborns with risk factors),
screening technology (otoacoustic emission (OAE) or
automated auditory brainstem response (AABR)), screen-
ing strategy (universal screening or risk screening), num-
ber of stages in the initial screening process (one or
two), detection of hearing loss (unilateral or bilateral),
setting (inpatient or outpatient), cost categories consid-
ered (development/implementation/organization/moni-
toring of the screening programme, tracking, screening
tests, diagnostic follow-up, treatment for detected cases
of hearing disorder, patient transportation for diagnostic
procedures and treatment, education, work time loss for
parents/adults with hearing disorders, productivity loss
due to hearing disorders/premature mortality), and com-
parators. Most of the studies evaluated different screen-
ing technologies [25,48-51,54-59]. Five economic
evaluations compared different screening strategies
[23,24,60-62]. Two studies analyzed different screening
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settings [52,65], and one study compared subjective and
objective screening tests [63]. Six of the economic eva-
luations were from the United States [51,55-57,60,62],
six from Germany [23,48,53,61,64,65], three from the
United Kingdom [52,54,63], two from Taiwan [58,59]
and Canada [25,50], and one each from Australia [24]
and the Netherlands [49].
The results of the application of the guidelines revealed
that most of the economic evaluations met the following
items:
 Study question (B.1.)
 Intervention (B.2.)
 Control (B.3.)
In contrast, the following items were inadequately met
or not considered at all:
 Model validation (C.7.)
 Health outcomes measured in natural units (D.1.),
adjusted by utility weights or health state preference
scores (D.2.), or measured in monetary units (D.3.)
 Measurement (E.1.b. and E.2.b.) and valuation (E.1.c.
and E.2.c.) of resource data
 Justification of discount rates (F.3.)
 ICER for the primary outcome measure (G.3.)
 Modelling uncertainty (H.2.)
 Generalizability and transferability of the economic
evaluation results (I.2.)
 Ethical and distributional issues (I.3.)
In economic evaluations of newborn hearing screen-
ing, one of the main problems refers to the time hori-
zon over which relevant costs and consequences
accrue. In most of the studies, the time horizon from
the initial screening test up to and including diagnos-
tic follow-up was considered. The time horizon of
seven economic evaluations was even restricted to the
initial screening test [50,51,53,54,58,59,64]. To assess
the cost-effectiveness of newborn hearing screening
vs. risk or no (regular) screening, a long time horizon
and a transsectoral perspective are needed, because
long-term cost savings due to early detection and
treatment are related to other sectors than the health
care sector – such as, for example, education and
labour. Four studies [24,25,60,63] used a societal per-
spective, three of which [24,25,60] considered a life-
time time horizon, but all long-term estimates heavily
relied on assumptions rather than long-term empirical
data. To date, the long-term effectiveness of newborn
hearing screening programmes has not been ad-
equately evaluated. In particular, valid data on patient-
relevant parameters, such as social skills, languageacquisition, educational development (e.g., school per-
formance), professional career, and quality of life are
sparse [66-69].
In general, the economic evaluations in newborn hear-
ing screening lack a clear and detailed description of
which cost categories were considered, how the asso-
ciated resource quantities were measured, and how the
resources were valued, which hinders the generalizability
and transferability of economic evaluation results. Most
of the studies only include the costs of screening and
diagnostic follow-up. Costs for the implementation of
the newborn hearing screening programme are only con-
sidered in some studies [48,56,63,65]. Furthermore, costs
of screening vary due to different factors, such as differ-
ent screening technologies (OAE or AABR), different
settings (inpatient or outpatient), number of stages in
the initial screening process (one-stage or two-stage), dif-
ferent target populations (all newborns or newborns with
risk factors), or detection of hearing loss (unilateral or
bilateral). In addition, measurement and valuation of
resources vary, which also hinders the comparability of
cost-effectiveness between studies. Furthermore, most
studies rely on resource estimates identified through lit-
erature review or collected retrospectively alongside ef-
fectiveness data, and report only average costs per child
screened or per child detected.
Instead of identifying the effectiveness of newborn
hearing screening in terms of a health outcome variable,
the standard approach to measuring effectiveness in all
but three studies simply was to count the number of
children screened or detected. Two further studies
[23,61] used the number of child months detected to
emphasize the importance of early detection and inter-
vention. There is only one study [52] using a health out-
come measure called “quality-weighted detected child
months”. This QALY-like measure is based on the as-
sumption that children with hearing losses detected earl-
ier would experience an improved quality of life;
however, empirical data in support of this assumption
are missing. Finally, only eight studies reported incre-
mental cost-effectiveness ratios [23-25,55,60,62,63,65]
which are relevant to decision making in health care.
Economic evaluations in newborn screening for inherited
metabolic disorders including MCADD by MS/MS
In newborn screening of inherited metabolic disorders,
the guidelines were applied to twelve economic evalua-
tions [70-81], of which an overview can be found in
Additional file 2. These studies were heterogeneous in
terms of disease prevalence, frequency of adverse out-
comes (e.g., morbidity and mortality), metabolic disor-
ders considered under MS/MS screening, and cost
categories considered. In these economic evaluations,
one (MCADD) up to 21 inherited metabolic disorders
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from 1.19 to 9 per 100,000 newborns. Five studies were
from the United States [73,75-77,80], two from Canada
[71,78], and one each from Australia [81], Finland [70],
France [79], the United Kingdom [74], and the Nether-
lands [72]. Ten of the twelve studies provided incremen-
tal cost-effectiveness ratios [70-73,75,77-81]. In the
remaining two studies MS/MS screening was found to
be cost saving [74,76]. The incremental cost-effectiveness
ratios varied widely due to different epidemiological and
clinical parameters, different outcome measures (life-
years gained vs. QALYs gained), and differences in the
number of conditions screened under MS/MS and in the
cost categories considered in the economic evaluations
(costs of screening and diagnostic follow-up, costs of im-
mediate and ongoing treatment, costs of non-medical
care, costs of productivity losses). For instance, only five
studies considered start-up costs of MS/MS screening
[70,76-79].
The results of the application of the guidelines revealed
that most of the economic evaluations met the following
items:
 Study question (B.1.)
 Intervention (B.2.)
 Target population (B.4.)
In contrast, the following items were inadequately met
or not considered at all:
 Model validation (C.7.)
 Health outcomes measured in monetary units (D.3.)
and non-health outcomes (D.5.)
 Method of valuing health benefits (D.2.b)
 Measurement (E.1.b. and E.2.b.) and valuation (E.1.c.
and E.2.c.) of resource data
 Justification of discount rates (F.3.)
 Generalizability and transferability of the economic
evaluation results (I.2.)
 Ethical and distributional issues (I.3.)
In economic evaluations of newborn screening for
inherited metabolic disorders, one of the main pro-
blems relates to the lack of epidemiological data, such
as the frequency of adverse outcomes with and with-
out screening in terms of morbidity and mortality
[12,13]. A further common weakness refers to the
health outcomes used in the economic analysis. In
half of the studies, life-years gained were used as a
health outcome measure, but mortality does not at-
tach great importance to the prevention of morbidity
[42]. In contrast, the quality adjusted life year (QALY)
incorporates both mortality and morbidity in a single
outcome measure. However, the validity of QALYestimates in newborn screening is limited [82-84]. In
newborn screening-related cost-utility analyses of MS/
MS, it is common to take published utility weights
from studies of adults with neurological impairments
caused by other disorders than metabolic ones [42],
although parent preferences for pediatric outcomes
are also available [85]. The application of these parent
preferences to published pediatric cost-utility analyses
showed that more than a third of these analyses
would change if such utilities were used [86]. In a re-
cent review it was found that QALY weights for
neurological impairments vary widely in pediatric eco-
nomic evaluations [87], an issue which is also related
to the economic evaluations considered here. To date,
appropriate health state classification instruments that
consider the dynamics of child development are lack-
ing, health state classification instruments suitable for
use in children aged 5 years and younger have not
been established, and the role of proxies for measur-
ing and valuing children’s health-related quality of life
is not fully understood [82]. However, a child-friendly
version of the EQ-5D is now available, namely the
EQ-5D-Y [88], which proved to be feasible, reliable,
and valid [89]. Nevertheless, further research is
needed in terms of the development of methods that
consider the health benefits of parents, and the conse-
quences of integrating different forms of utility meas-
urement in children and adults [82] in order to
address potential harms arising from early detection
or false-positive test results.
Discussion
To date, no specific guidelines for assessing and im-
proving the methodological quality of economic eva-
luations in newborn screening have been developed.
Only one study was found that established “a general-
ised model of cost-effectiveness appraisal“ in the area
of newborn screening for rare metabolic conditions
using MS/MS, in order to identify the key variables
that need to be considered to estimate costs and
effects of MS/MS and alternatives [13]: these key vari-
ables comprise general items, such as prevalence of
the conditions screened for with and without screen-
ing, or sensitivity and specificity of MS/MS and alter-
natives for the various conditions, screening costs,
treatment costs, downstream health costs, societal
costs, mortality, and morbidity. These newborn
screening-specific guidelines were developed to high-
light the need for greater standardization in the meth-
odological quality of newborn screening-related
economic evaluations and to ensure that future eco-
nomic evaluations in newborn screening are con-
ducted consistently and appropriately in order to
enhance the comparability, generalizability and
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born screening. Furthermore, the high economic and
human burden of diseases that can be detected early
through newborn screening programmes gives such
programmes a high priority in resource allocation,
and underscores the need for specific guidelines. The
application of the guidelines revealed methodological
flaws regarding perspective, time horizon, discounting,
use of assumptions rather than data, measuring and
valuing health outcomes and resource data, modelling
in terms of uncertainty and validation, transparency of
reporting, generalizability, and ethical and distribu-
tional issues. Using the Pediatric Quality Appraisal
Questionnaire [90], a quality appraisal of pediatric
health economic evaluations published between 1980
and 1999 revealed that these economic evaluations
were of good quality for “economic evaluation”, “com-
parators”, “target population”, “discounting” and “con-
clusions”, and only of poor quality for “perspective”,
“incremental analysis”, and “conflict of interest” [91].
In this study, it was found that the quality domains of
the specific guidelines developed here are fulfilled dif-
ferently by the economic evaluations in the areas of
newborn screening for inherited metabolic disorders
including MCADD by MS/MS and newborn hearing
screening. For example, in opposite to the economic
evaluations in newborn hearing screening, all eco-
nomic evaluations of newborn screening for inherited
metabolic disorders including MCADD by MS/MS
provide incremental cost-effectiveness ratios.
The guidelines proposed have several limitations.
First, they can be applied to all economic evaluations
in newborn screening. Therefore, issues specific to
certain diseases detectable by newborn screening or
technologies of newborn screening are not addressed
in these guidelines. For instance, there is controversy
in the literature whether newborn screening for all
detectable disorders with MS/MS is cost-effective
[92,93]. This question, from which methodological
and ethical issues arise, is common for screening
technologies that can be used to detect multiple con-
ditions such as MS/MS or DNA-based screening.
Cipriano et al. [78] suggest that variation in MS/MS
sensitivity and specificity to detect other disorders,
different treatment costs, and different potential bene-
fits from early diagnosis and treatment may require
the independent evaluation of each disease. Further-
more, researchers have still to elaborate a method-
ology which enables the economic evaluation of
health technologies with a one-test, many-disorders
approach – i.e., the simultaneous detection of a panel
of disorders in a single individual. Second, the guide-
lines should be considered a starting point for asses-
sing and improving the methodological quality ofeconomic evaluations in newborn screening. As meth-
odological issues advance, the guidelines should be
regularly updated. Regarding issues of modelling and
transferability, more detailed assessments are available
[21,43,94,95]. Furthermore, the guidelines do not re-
sult in a quality score whose value, however, may be
critically assessed [96], but in a structured abstract
which is an alternative method of communicating the
information to decision makers. In a study by Thur-
ston et al. [97] it was found that decision makers pre-
fer a more detailed structured abstract in addition to
a very short summary.
Conclusions
These guidelines were provided in order to assess
and improve the methodological quality of economic
evaluations in newborn screening. The application to
economic evaluations in the areas of newborn hearing
screening, and newborn screening for inherited meta-
bolic disorders including MCADD by MS/MS high-
lights important issues of economic evaluations in
these two areas of newborn screening and under-
scores the need for their greater consideration in fu-
ture newborn screening-related economic evaluations.
The variation in methodological quality of the eco-
nomic evaluations in newborn screening which is
detected through application of the guidelines, and
which limits the comparability, generalizability and
transferability of economic evaluation results, reveals
the necessity for specific guidelines regarding the
methods for conducting sound economic evaluations
in newborn screening.
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